ERK/MAPK signalling pathway and tumorigenesis
YJ Guo, WW Pan, SB Liu… - Experimental and …, 2020 - spandidos-publications.com
Mitogen-activated protein kinase (MAPK) cascades are key signalling pathways that
regulate a wide variety of cellular processes, including proliferation, differentiation …
regulate a wide variety of cellular processes, including proliferation, differentiation …
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri… - Blood, The Journal …, 2016 - ashpublications.org
A revision of the nearly 8-year-old World Health Organization classification of the lymphoid
neoplasms and the accompanying monograph is being published. It reflects a consensus …
neoplasms and the accompanying monograph is being published. It reflects a consensus …
[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …
cancer testing has highlighted the importance and potential benefits of standardizing the …
[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
Mutations driving CLL and their evolution in progression and relapse
Which genetic alterations drive tumorigenesis and how they evolve over the course of
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …
Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR
Inhibition of the BRAF (V600E) oncoprotein by the small-molecule drug PLX4032
(vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer …
(vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer …
The MAPK pathway across different malignancies: a new perspective
M Burotto, VL Chiou, JM Lee, EC Kohn - Cancer, 2014 - Wiley Online Library
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway
is activated by upstream genomic events and/or activation of multiple signaling events in …
is activated by upstream genomic events and/or activation of multiple signaling events in …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
L Wang, MS Lawrence, Y Wan… - … England Journal of …, 2011 - Mass Medical Soc
Background The somatic genetic basis of chronic lymphocytic leukemia, a common and
clinically heterogeneous leukemia occurring in adults, remains poorly understood. Methods …
clinically heterogeneous leukemia occurring in adults, remains poorly understood. Methods …
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
AKS Salama, S Li, ER Macrae, JI Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …